Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo

DocumentFichier
Fichier pdf chargé le 07/12/2018 à 09:47:05
Accès identifié
(version éditeur)
Request
TitreAntimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo
Type de publicationArticle de revue
AuteurRozenbaum, René T, Su, Linzhu, Umerska, Anita-Monika, Eveillard, Matthieu
1, 2
, Håkansson, Joakim, Mahlapuu, Margit, Huang, Fan, Liu, Jianfeng, Zhang, Zhenkun, Shi, Linqi, van der Mei, Henny C, Busscher, Henk J, Sharma, Prashant K
EditeurElsevier
TypeArticle scientifique dans une revue à comité de lecture
Année2019
LangueAnglais
Date10 Janvier 2019
Pagination73-83
Volume293
Titre de la revueJournal of controlled release
ISSN1873-4995
Mots-clésantimicrobial peptides, Biofilms, Monolaurin, Nanocapsules, Wound-healing, Zeta potentials
Résumé en anglais

Bacterial infections are mostly due to bacteria in their biofilm-mode of growth, while penetrability of antimicrobials into infectious biofilms and increasing antibiotic resistance hamper infection treatment. In-vitro, monolaurin lipid nanocapsules (ML-LNCs) carrying adsorbed antimicrobial peptides (AMPs) displayed synergistic efficacy against planktonic Staphylococcus aureus, but it has not been demonstrated, neither in-vitro nor in-vivo, that such ML-LNCs penetrate into infectious S. aureus biofilms and maintain synergy with AMPs. This study investigates the release mechanism of AMPs from ML-LNCs and possible antimicrobial synergy of ML-LNCs with the AMPs DPK-060 and LL-37 against S. aureus biofilms in-vitro and in a therapeutic, murine, infected wound-healing model. Zeta potentials demonstrated that AMP release from ML-LNCs was controlled by the AMP concentration in suspension. Both AMPs demonstrated no antimicrobial efficacy against four staphylococcal strains in a planktonic mode, while a checkerboard assay showed synergistic antimicrobial efficacy when ML-LNCs and DPK-060 were combined, but not for combinations of ML-LNCs and LL-37. Similar effects were seen for growth reduction of staphylococcal biofilms, with antimicrobial synergy persisting only for ML-LNCs at the highest level of DPK-060 or LL-37 adsorption. Healing of wounds infected with bioluminescent S. aureus Xen36, treated with ML-LNCs alone, was faster when treated with PBS, while AMPs alone did not yield faster wound-healing than PBS. Faster, synergistic wound-healing due to ML-LNCs with adsorbed DPK-060, was absent in-vivo. Summarizing, antimicrobial synergy of ML-LNCs with adsorbed antimicrobial peptides as seen in-vitro, is absent in in-vivo healing of infected wounds, likely because host AMPs adapted the synergistic role of the AMPs added. Thus, conclusions regarding synergistic antimicrobial efficacy, should not be drawn from planktonic data, while even in-vitro biofilm data bear little relevance for the in-vivo situation.

URL de la noticehttp://okina.univ-angers.fr/publications/ua18228
DOI10.1016/j.jconrel.2018.11.018
Lien vers le document

https://www.sciencedirect.com/science/article/pii/S0168365918306631?via%...

Titre abrégéJ Control Release
Identifiant (ID) PubMed30465823